Skip to main content Skip to search Skip to main navigation

IPEC: Position Paper on Nitrosamine Risks in Excipients

The IPEC (International Pharmaceutical Excipients Council Federation) has published a summarizing position paper on "The Role of Excipients in Determining N-Nitrosamine Risks for Drug Products". The 7-page paper describes the IPEC Federation’s position on the role of excipients when conducting N-nitrosamine risk assessments for medicinal products.

According to the IPEC, the issue for the paper is that the presence of N-nitrosamines in drug products continues to be a global concern. Excipients are considered as a potential risk factor during the drug product risk assessment. The focus of this position paper is to expand on the potential contribution excipients may or may not have on the formation of nitrosamines in final drug products. The presence of nitrites and vulnerable amines in excipients are also considered.

Even though excipient manufacturers are under no specific regulatory requirement to provide risk assessments on nitrosamines to regulatory agencies, the IPEC considers a risk-based cooperation between the pharmaceutical manufacturer and an excipient supplier appropriate. It is necessarily in the interest of an excipient manufacturer to supply safe excipients. Water in various qualities, raw materials, and excipient processing conditions could be sources of nitrites and nitrates. Excipient suppliers should carefully evaluate the potential risk related to their excipients. This will assist medicinal product manufacturers to fulfill their regulatory obligation which is to conduct risk assessments for their drug products.


Source:

IPEC: The Role of Excipients in Determining N-Nitrosamine Risks for Drug Products

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

EMA: Concept Paper for the Revision of Annex 3 on Radiopharmaceuticals

The EMA has published a concept paper outlining a future revision of Annex 3 (Manufacture of Radiopharmaceuticals) of the EU GMP Guidelines. The paper was developed in collaboration with PIC/S and adopted by the GMDP Inspectors Working Group (IWG) at its November meeting.

Read more
EMA: Q&A on QP Certification Without Physical EU Import

EMA: Q&A on QP Certification Without Physical EU Import

The EMA has published a new Q&A addressing QP certification for batches that are neither manufactured within the EU/EEA nor intended for the EU/EEA market, and that are not physically imported into the EU/EEA.

Read more
EU: Agreement on the Pharmaceutical Package

EU: Agreement on the Pharmaceutical Package

On 11 December, the European Commission, the European Parliament, and the Council of the European Union reached a provisional agreement to update Europe's medicinal products regulatory framework.

Read more
EMA: Updated Q&As for Biological Medicinal Products

EMA: Updated Q&As for Biological Medicinal Products

EMA has updated its Q&A on biological medicinal products, addressing topics that previously required clarification or were subject to differing interpretation. The latest revision adds six new questions and updates several existing answers.

Read more
ICH: New Recommendations for the Manufacture of ATMPs

ICH: New Recommendations for the Manufacture of ATMPs

The ICH’s Cell and Gene Therapy Discussion Group (CGTDG), which was established in May 2023, has provided recommendations with regard to future Advanced Therapy Medicinal Products (ATMPs) Related Guidelines.

Read more
GMP Publishing Embarks on a new Digital Chapter

GMP Publishing Embarks on a new Digital Chapter

After months of intensive work, creative ideas, and technical finesse, the time has finally come: the GMP Verlag website has been given a fresh new look.
Read more
Previous
Next